Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoitesD A Herrington, Myron M. Levine, Michael R. Hollingdale et al.|Nature|1987Cited by 503
Safety, infectivity, immunogenicity, and in vivo stability of two attenuated auxotrophic mutant strains of Salmonella typhi, 541Ty and 543Ty, as live oral vaccines in humans.Myron M. Levine, M F Edwards, D A Herrington et al.|Journal of Clinical Investigation|1987Cited by 189
Specific immunoglobulin A-secreting cells in peripheral blood of humans following oral immunization with a bivalent Salmonella typhi-Shigella sonnei vaccine or infection by pathogenic S. sonneiLillian Van De Verg, Myron M. Levine, D A Herrington et al.|Infection and Immunity|1990Cited by 74
Evidence for a 6.5-day minimum exoerythrocytic cycle for Plasmodium falciparum in humans and confirmation that immunization with a synthetic peptide representative of a region of the circumsporozoite protein retards infectionJames R. Murphy, D. F. Clyde, Shahida Baqar et al.|Journal of Clinical Microbiology|1989Cited by 37
Human studies with synthetic peptide sporozoite vaccine (NANP)3-TT and immunization with irradiated sporozoites.D A Herrington, R S Nussenzweig, D. F. Clyde et al.|PubMed|1990Cited by 27